OTCMKTS:PURE PURE Bioscience (PURE) Stock Price, News & Analysis $0.07 +0.00 (+5.87%) As of 03:58 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartEarningsNews and TrendsSEC Filings About PURE Bioscience Stock (OTCMKTS:PURE) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get PURE Bioscience alerts:Sign Up Key Stats Today's Range$0.07▼$0.0850-Day Range$0.06▼$0.0952-Week Range$0.04▼$0.10Volume1,700 shsAverage Volume37,266 shsMarket Capitalization$9.37 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview PURE Bioscience, Inc. develops and commercializes antimicrobial products based on its proprietary silver dihydrogen citrate (SDC) technology. SDC is designed to provide broad-spectrum antimicrobial activity while serving as the active ingredient in disinfecting, sanitizing, and hygiene formulations. The company’s product portfolio has included PURE-branded solutions for hard-surface disinfection and sanitation, as well as applications in food safety, commercial and industrial settings, healthcare, and other environments where microbial control is important. Its products are intended for use on surfaces, equipment, and other areas requiring cleaning and antimicrobial protection. PURE Bioscience has historically marketed its products in the United States and has pursued additional commercial opportunities through distributors and strategic partners. The company is headquartered in California. Information about its current leadership and geographic operations is limited and may change over time.AI Generated. May Contain Errors. Read More PURE Bioscience Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks8th Percentile Overall ScorePURE MarketRank™: 0.40708998831 of 5 starsPURE Bioscience scored higher than 8% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for PURE Bioscience. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of PURE Bioscience is -2.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of PURE Bioscience is -2.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.02% of the float of PURE Bioscience has been sold short.Short Interest Ratio / Days to CoverPURE Bioscience has a short interest ratio ("days to cover") of 0.24, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in PURE Bioscience has recently increased by 15.14%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPURE Bioscience does not currently pay a dividend.Dividend GrowthPURE Bioscience does not have a long track record of dividend growth. News and Social Media2.3 / 5News SentimentN/A News SentimentPURE Bioscience has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 1 news article for PURE Bioscience this week, compared to 0 articles on an average week. Company Ownership0.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, PURE Bioscience insiders have not sold or bought any company stock.Percentage Held by Insiders35.56% of the stock of PURE Bioscience is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsPURE Bioscience has minimal institutional ownership at this time.Read more about PURE Bioscience's insider trading history. Receive PURE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for PURE Bioscience and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PURE Stock News HeadlinesPURE Bioscience (OTCMKTS:PURE) Shares Cross Above Two Hundred Day Moving Average - Here's What HappenedOctober 14 at 3:01 AM | americanbankingnews.comPURE Bioscience (OTCMKTS:PURE) Share Price Breaks Above 200-Day Moving Average - Time to Sell?October 6, 2026 | americanbankingnews.comElon Musk’s 4th Wealth Window Set to Open by October 30Jeff Brown, the analyst who flagged Bitcoin, Tesla, and Nvidia early, is tracking Elon Musk's next move. He points to a new AI project tied to Musk's Cybercab reveal. Brown says Musk has opened major investment windows before, with PayPal, Tesla, and SpaceX marking milestones in tech history. He believes a fourth may open by October 30.October 16 at 1:00 AM | Brownstone Research (Ad)Pure Bioscience Inc.August 12, 2026 | marketwatch.comPURE Bioscience Reports Fiscal Third Quarter 2026 Financial ResultsJune 15, 2026 | businesswire.comPurecore Strengthens Technical Advisory Expertise with Nuclear Fuel Cycle and Uranium Enrichment Specialist, Ted Rygas, PhDJune 15, 2026 | globenewswire.comPurecore Announces up to $1.5 Million Non-Brokered Private PlacementJune 5, 2026 | globenewswire.comPurecore Announces Listing on the Frankfurt Stock ExchangeJune 4, 2026 | globenewswire.comSee More Headlines PURE Stock Analysis - Frequently Asked Questions How have PURE shares performed this year? PURE Bioscience's stock was trading at $0.0420 at the beginning of the year. Since then, PURE stock has increased by 71.7% and is now trading at $0.0721. How were PURE Bioscience's earnings last quarter? PURE Bioscience (OTCMKTS:PURE) issued its earnings results on Monday, June, 15th. The company reported ($0.01) earnings per share (EPS) for the quarter. The company earned $0.51 million during the quarter. How do I buy shares of PURE Bioscience? Shares of PURE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of PURE Bioscience own? Based on aggregate information from My MarketBeat watchlists, some other companies that PURE Bioscience investors own include Aurora Cannabis (ACB), Novavax (NVAX), Cresco Labs (CRLBF), Aurora Cannabis (ACB), Canopy Growth (CGC), DraftKings (DKNG) and Broadcom (AVGO). Company Calendar Last Earnings6/15/2026Today10/16/2026Fiscal Year End7/31/2027Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Healthcare Equipment & Supplies Sub-IndustryN/A Current SymbolOTCMKTS:PURE CIK1006028 Webwww.purebio.com Phone(619) 596-8600Fax619-596-8790Employees10Year Founded1992Profitability EPS (Trailing Twelve Months)($0.03) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$2.40 million Net Margins-109.59% Pretax Margin-65.45% Return on EquityN/A Return on Assets-321.74% Debt Debt-to-Equity RatioN/A Current Ratio0.42 Quick Ratio0.36 Sales & Book Value Annual Sales$2.20 million Price / Sales4.26 Cash FlowN/A Price / Cash FlowN/A Book Value($0.05) per share Price / Book-1.44Miscellaneous Outstanding Shares130,020,000Free Float83,784,000Market Cap$9.37 million OptionableNot Optionable Beta0.33 Social Links The 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (OTCMKTS:PURE) was last updated on 10/16/2026 by MarketBeat.com Staff. From Our PartnersElon Musk’s 4th Wealth Window Set to Open by October 30Jeff Brown, the analyst who flagged Bitcoin, Tesla, and Nvidia early, is tracking Elon Musk's next move. He po...Brownstone Research | SponsoredFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leadin...Weiss Ratings | SponsoredSpaceX minted 4400 millionaires in a single daySpaceX minted 4,400 millionaires in a single day, and Tesla has turned more than 5,000 employees into milliona...Behind the Markets | SponsoredTrump’s issues shocking Executive Order on U.S. DollarThree days into his second term, President Trump signed Executive Order 14178 a move the press barely covered....Banyan Hill Publishing | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredA new income category is drawing serious money - here's whyForbes recently called a new category of exchange-traded income funds a 'golden era,' and Bloomberg noted the ...Investors Alley | SponsoredThe oil check Munger called his best dealCharlie Munger's $1,000 oil investment in 1962 later paid about $70,000 a year, totaling roughly $1 million ov...The Oxford Club | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PURE Bioscience Please log in to your account or sign up in order to add this asset to your watchlist. Share PURE Bioscience With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
